MARTEN TRANSPORT ANNOUNCES SECOND QUARTER RESULTS

MARTEN TRANSPORT LTD (MRTN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_990661.htm EXHIBIT 99.1 ex_990661.htm Exhibit 99.1 MARTEN TRANSPORT ANNOUNCES SECOND QUARTER RESULTS MONDOVI, Wis., July 23, 2026 (GLOBE NEWSWIRE) -- Marten Transport, Ltd. (Nasdaq/GS:MRTN) today reported net income of $5.3 million, or 7 cents per diluted share, for

Original reporting
Published Jul 23, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 23, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MRTN
Neutral
medium confidence
Mentioned
$MRTN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MRTNNeutralMed
01

Why it matters

The filing quantifies earnings, revenue composition (including fuel surcharges), and operating expense ratios, while management attributes freight market tightening to regulatory enforcement and the Supreme Court’s Montgomery broker-liability ruling.

02

Market read

Traders can reassess near-term earnings power and pricing/capacity assumptions using the reported Q2 metrics and the stated freight-market tightening drivers.

03

What to watch

Fuel surcharge revenue rose (to $38.3M in Q2), so investors may adjust for how much of the earnings change is pass-through versus underlying demand and cost control.

Relevance 7/10Novelty 7/10Timing: after-hours today, following SEC 8-K release of Q2 results

Background

This is an SEC 8-K with Exhibit 99.1 reporting Marten Transport’s second-quarter 2026 results and balance sheet updates.

Company-level read

Ticker impact

$MRTNNeutralMedium confidence
Context

Marten Transport reported Q2 2026 net income of $5.3M (7 cents/diluted) versus $7.2M (9 cents) in Q2 2025, with revenue and margin details.

Expected impact

Near-term trading likely hinges on whether investors focus on sequential margin improvement and freight tightening narrative versus the YoY earnings decline.

Evidence & confidence

The filing provides concrete quarterly earnings, revenue, operating income, and expense ratios, plus management commentary linking freight capacity contraction to regulatory enforcement and broker-liability precedent.

Market effects

Highlights how regulatory enforcement around CDL compliance and ELD fraud could tighten capacity for truckload and brokerage carriers.

Primarily US freight market dynamics, with potential read-through to Midwest-based logistics peers.

Limited direct global impact; mostly domestic trucking capacity and pricing conditions.

Counterpoint

The sequential improvement may not persist if revenue softness returns, since operating income and operating revenue were lower YoY.

Key entities

  • Marten Transport, Ltd.

    Nasdaq-listed truckload and brokerage carrier reporting Q2 2026 results in an 8-K.

  • Montgomery broker-liability ruling

    Supreme Court decision cited as contracting freight capacity by affecting negligent hiring claims against freight brokers.

Related articles

$MRTNMed

MARTEN TRANSPORT ANNOUNCES THIRD QUARTER RESULTS

MARTEN TRANSPORT LTD (MRTN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MARTEN TRANSPORT ANNOUNCES THIRD QUARTER RESULTS MONDOVI, Wis., October 22, 2026 (GLOBE NEWSWIRE) -- Marten Transport, Ltd. (Nasdaq/GS:MRTN) today reported a 30.7% improvement in net income to $2.9 million, or 4 cents per diluted share, for the third quarter ended Se

$SGPMedAI 8/10

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates • Acquired Advanced Vision Science, Inc. (AVS), securing scalable commercial intraocular lens (IOL) manufacturing capacity for its Phase 3 lead product candidate the Bimatopro

$ONDSHighAI 8/10

Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook

Ondas Inc. (ONDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ondas Posts Record Q3 2026 Revenue of $167.5 Million on Strong Bookings and Backlog Growth; Raises Full-Year Outlook Record Q3 revenue of $167.5 million, up 100% sequentially and more than 16-fold year over year; pro forma organic revenue grew 64% year-over-year Capt

$MOVEMed

Corvex Reports Third Quarter 2026 Results

Corvex, Inc. (MOVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corvex Reports Third Quarter 2026 Results ARLINGTON, Va., Nov. 12, 2026 /PRNewswire/ -- Corvex, Inc. (Nasdaq: MOVE), an engineering-led AI computing platform specializing in GPU-accelerated infrastructure for AI workloads, today reported financial results for the thi

$AVLNMed

Avalyn Pharma 3Q 2026: EPS ($0.67) — 10-Q Summary

Avalyn Pharma reported a wider net loss of $29.66M in Q3 2026, up 25.7% YoY, driven by higher R&D and administrative expenses. Diluted EPS was ($0.67). The company provided updates on clinical trials for AP01, AP02, and AP03, with topline data expected in late 2027. R&D costs increased by $3.4M, primarily due to AP02 trial expenses.